DCPH Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.32%, SMA50 20.33%, SMA200 61.93%). The stock’s 14-day RSI is 85.58 (overbought), while the ATR of 0.2 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.08% below its high and over 158.48% above its low.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) closed at $25.59 USD, gaining $0.02 (0.08%) from the previous close of $25.57. The stock is currently trading near its 52-week high $9.90 and $25.61. With a market capitalization of about $2.21 billion, Deciphera Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.18). Key stats such as the average daily volume over the past year has been around 1.86 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Deciphera Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Steven L. Hoerter, the company employs approximately 355 people and listed since September 28, 2017. Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.

Deciphera Pharmaceuticals, Inc. generated EPS of -$2.21 over the past year. Five-year average earnings growth is 4.07%. Wall Street analysts project EPS growth of 21.0% annually over the next five years. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at -$0.51. Next year's EPS is expected at $1.13. Deciphera Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 10, 2024, missed forecasts by -5.45%. The prior quarter beat by -6.9%. Over the last six quarters, Apple has recorded several small beats. These include 7.14% in February 07, 2023.

Deciphera Pharmaceuticals, Inc. has 86.48 million shares outstanding. The public float is 46.43 million shares, elevated short interest at 6.33% of float. This equals 3.92 million shares. The short ratio is 1.05 days. Institutional investors hold 100.72% of the float. Insiders own 28.48%. Brightstar Associates LLC holds 19.72 million shares, Sherman Matthew L has 108.74 thousand shares and Kelly Thomas Patrick has 80.35 thousand shares.

Deciphera Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $17.21. This means the shares are trading above this model’s fair value.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares are up 58.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Deciphera Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -11.17. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $35.64, suggesting 39.27% upside. Our AI forecast model points to short-term strength (14.15% over two weeks), a medium-term fall (-34.58% over three months), and a longer-term gain (87.42% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Deciphera Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.15%, with price expected at $29.21 by June 25, 2024, within a range of $25.36 to $32.55 3-Month Outlook: Projected fall of -34.58%, reaching $16.74 by September 09, 2024, with a range of $15.63 to $17.85. 1-Year Outlook: Projected gain of 87.42%, with price at $47.96 by June 11, 2025, within a range of $44.51 to $51.40.

Deciphera Pharmaceuticals, Inc. trades at a P/E ratio of -11.17, slightly below the S&P 500 average, with a price-to-sales ratio of 13.55 and a price-to-book ratio of 6.2 trading at moderately above to book value. The P/FCF stands at -15.01, also below market averages.